VEGFR2/CD309 Protein (AA 807-1356) (His-GST)

N° du produit ABIN7317118

Cette protéine Recombinant VEGFR2/CD309 est produite dans Baculovirus infected Insect Cells.

Aperçu rapide pour VEGFR2/CD309 Protein (AA 807-1356) (His-GST) (ABIN7317118)

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Type de proteíne: Recombinant

Activité biologique: Active

Origine: Humain

Source: Baculovirus infected Insect Cells

Pureté: > 78 % as determined by reducing SDS-PAGE.

Détail du produit

Attributs du protein: AA 807-1356

Purification/Conjugué: Cette VEGFR2/CD309 protéine est marqué à la His-GST.

Fonction: Recombinant Human VEGFR2/Flk-1/KDR Protein (His &GST Tag)

Séquence: Asp807-Val1356

Attributs du produit: A DNA sequence encoding the human KDR (NP_002244) (Asp807-Val1356) was fused with the N-terminal polyhistidine-tagged GST tag at the N-terminus.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: The specific activity was determined to be 10 nmol/min/mg using Poly(Glu, Tyr) 4:1 as substrate.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Supplied as sterile solution of 50 mM Tris, 100 mM NaCl, pH 8.0, 10 % glycerol, 2 mM GSH

Stock: -20 °C

Stockage commentaire: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

Date de péremption: 6 months

Détail du antigène

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: VEGFR2/Flk-1/KDR

Sujet: CD309,FLK-1,FLK1,Fetal liver kinase 1,Flk-1,KDR,Kinase insert domain receptor,Protein-tyrosine kinase receptor flk-1,VEGFR,VEGFR-2,VEGFR2,Vascular endothelial growth factor receptor 2,VEGFR2, also called as KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as a major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners, thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling is critical to endothelial cell survival, maintenance of the vasculature and alveolar structure and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.

Poids moléculaire:

Calculated MW: 89.3 kDa

Observed MW: 110 kDa

ID gène: 3791

NCBI Accession: NP_002244

UniProt: P35968

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling